4//SEC Filing
Schmitz Patrick 4
Accession 0001567619-20-005413
CIK 0001444380other
Filed
Mar 2, 7:00 PM ET
Accepted
Mar 3, 2:49 PM ET
Size
31.0 KB
Accession
0001567619-20-005413
Insider Transaction Report
Form 4
NEVRO CORPNVRO
Schmitz Patrick
Vice President, Operations
Transactions
- Exercise/Conversion
Common Stock
2020-02-28$42.30/sh+5,156$218,099→ 61,542 total - Sale
Common Stock
2020-02-28$126.47/sh−4,604$582,265→ 56,938 total - Sale
Common Stock
2020-02-28$130.82/sh−600$78,495→ 18,658 total - Exercise/Conversion
Stock Option (Right to Buy)
2020-02-28−7,312→ 5,688 totalExercise: $76.81Exp: 2027-11-13→ Common Stock (7,312 underlying) - Exercise/Conversion
Common Stock
2020-02-28$87.62/sh+10,833$949,187→ 49,074 total - Exercise/Conversion
Common Stock
2020-02-28$76.81/sh+7,312$561,635→ 56,386 total - Sale
Common Stock
2020-02-28$127.06/sh−7,404$940,773→ 49,534 total - Sale
Common Stock
2020-02-28$128.25/sh−2,758$353,722→ 46,776 total - Exercise/Conversion
Stock Option (Right to Buy)
2020-02-28−5,156→ 11,344 totalExercise: $42.30Exp: 2028-11-26→ Common Stock (5,156 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2020-02-28−19,583→ 417 totalExercise: $57.89Exp: 2026-03-13→ Common Stock (19,583 underlying) - Exercise/Conversion
Common Stock
2020-02-28$57.89/sh+19,583$1,133,660→ 38,241 total - Exercise/Conversion
Stock Option (Right to Buy)
2020-02-28−10,833→ 2,500 totalExercise: $87.62Exp: 2026-11-15→ Common Stock (10,833 underlying) - Sale
Common Stock
2020-02-28$129.34/sh−17,205$2,225,262→ 29,571 total - Sale
Common Stock
2020-02-28$130.13/sh−10,313$1,342,058→ 19,258 total
Footnotes (12)
- [F1]Includes 11,397 restricted stock units.
- [F10]1/48th of the shares subject to the option vest on each monthly anniversary measured from November 5, 2016 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
- [F11]1/48th of the shares subject to the option vest on each monthly anniversary measured from November 14, 2017 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
- [F12]1/48th of the shares subject to the option vest on each monthly anniversary measured from November 27, 2018 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
- [F2]The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
- [F3]The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $125.69 to $126.685, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F4]The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $126.695 to $127.69, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F5]The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $127.70 to $128.695, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F6]The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $128.71 to $129.705, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F7]The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $129.72 to $130.65, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F8]The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $130.74 to $130.95, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F9]25% of the shares subject to the option vest on the first anniversary measured from March 14, 2016 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest in thirty-six (36) successive and equal monthly installments thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
Documents
Issuer
NEVRO CORP
CIK 0001444380
Entity typeother
Related Parties
1- filerCIK 0001669489
Filing Metadata
- Form type
- 4
- Filed
- Mar 2, 7:00 PM ET
- Accepted
- Mar 3, 2:49 PM ET
- Size
- 31.0 KB